High blood pressure and calcium antagonism.
Calcium ions are intimately involved in many aspects of cardiovascular function. Modification of calcium homeostasis therefore represents a key target for pharmacological intervention to achieve therapeutic control of hypertension. The calcium channel blockers (CCBs) act by blocking calcium influx through voltage-dependent L (long-acting) channels without affecting calcium release from the sarcoplasmic reticulum. The effect of blocking these channels is a decrease in the intracellular calcium concentration, which reduces vascular smooth muscle tone. The subsequent decrease in peripheral resistance causes a decrease in systemic blood pressure. The CCBs also decrease myocardial contractility, which decreases myocardial oxygen consumption. Overall, the CCBs at therapeutic doses improve the efficiency of ventricular function. They also have a number of other beneficial effects, including an antiproliferative effect. The CCBs in clinical use vary according to their relative selectivities for vascular and cardiac tissue and their applicability to the treatment of hypertension or ischaemic heart disease. The first-generation CCBs (verapamil, nifedipine and diltiazem) are associated with a relatively short duration of action and unwanted cardiovascular effects that were related to poor vascular selectivity. In addition, nifedipine was associated with a very rapid onset of action that caused a sudden vasodilation and reflex tachycardia in some patients. The newer second-generation CCBs, for example the dihydropyridines, amlodipine, felodipine and nisoldipine, show greatly improved vascular selectivity and longer durations of action, achieved in part by novel controlled-release dosage forms. They bind to target receptors in a slow and sustained fashion, producing a smooth onset of action and 24-hour control of blood pressure. Once-daily dosing of these longer-acting agents improves patient compliance and is associated with a good side-effect profile. The second-generation CCBs are suitable antihypertensive agents for a wide range of patients, including the elderly and black patients, and those with concomitant diseases that preclude the use of other antihypertensives.
Palma-Gámiz
J L
JL
Service of Cardiology, Hypertensive Cardiomyopathy Unit, Ramón y Cajal Hospital, Madrid, Spain.
D002118:Calcium / Q000378:metabolism / Q000502:physiology; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002319:Cardiovascular System / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D012519:Sarcoplasmic Reticulum / Q000378:metabolism; D014655:Vascular Resistance / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects
D002121:Calcium Channel Blockers; D002118:Calcium